Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Primary Immunodeficiency
With the difficulty in access to PPSV23 as the new pneumonia vaccine is now standard (non polysaccharide vaccine), have you used MPSV4 (meningococcal) vaccine for evaluation of response to polysaccharide vaccine?
Have you used this for adults, children, or both?
Related Questions
How would you treat autologous GVHD after a thymic transplant but with no thymopoeisis?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
Is there any genetic testing available for the CDHR3 receptor?
Has anyone incidentally diagnosed IgA deficiency in a patient who does not present with any recurrent infections?
Is there any value to IgG subclasses in assessing immune deficiency in a patient with normal IgG levels?
Do you recommend weekly SQ immunoglobulin replacement for an asplenic patient who only responded to 4/23 pneumococcal serotypes after the Prevnar 20 vaccine?
What are the implications of checking post-vaccine titers after administration of Prevnar 20 compared to PPSV23?
Should the RSV vaccine be administered to pregnant mothers even if it is not seasonally circulating but they are 32-36 weeks pregnant?
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?